

#12 B<sup>116</sup>  
5-9-01  
P.2.

MAY 04 2001  
PATENT & TRADEMARK OFFICE

RECEIVED  
MAY 08 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name		Barbara M. Weatherly	
Signature		Date	
<i>Barbara M. Weatherly</i>		May 1, 2001	

TECH CENTER 1600/2900

<b>AMENDMENT UNDER 37 C.F.R. §1.116</b>  Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket Confirmation No.	AERX061 Unknown
	First Named Inventor	Gonda
	Application Number	09/330,903
	Filing Date	June 11, 1999
	Group Art Unit	1632
	Examiner Name	R. Schnizer
	Title	METHODS OF DELIVERING AEROSOLIZED POLYNUCLEOTIDES TO THE RESPIRATORY TRACT

Sir:

This amendment is responsive to the final Office Action dated November 17, 2000 for which a three-month period for response was given making this response due on or before February 17, 2001. A Petition for a three-Month Extension of Time is submitted herewith, making this amendment due on or before May 17, 2001. In view of the amendments to the claims and the remarks put forth below, reconsideration and allowance are respectfully requested. Applicants note that those claims not amended herein are being reiterated solely for the convenience of the Examiner.

05/07/2001 AHONDAF1 00000015 500815 09330903

I. AMENDMENTS 01 FC:203 144.00 CH  
02 FC:202 440.00 CH

IN THE CLAIMS

Please cancel claims 1-20 without prejudice to renewal.

Please enter new claims 21-56, as shown below.

21. (New) A method of administering a condensed polynucleotide by inhalation, comprising:
- a) determining a patient's total respiratory tract capacity;
  - b) inhaling a measured volume of particle free air wherein the measured volume is related to the total respiratory tract volume and further related to a region of the lung targeted for treatment;
  - c) releasing a volume of aerosol comprising particles of a condensed polynucleotide in a formulation wherein the volume released is related to the total respiratory tract volume and further related to a region of respiratory tract targeted for treatment; and